A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Trial Profile

A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin; Cytarabine; Dexamethasone
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 10 May 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 14 Jul 2014 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top